Mahmud Azra, Feely John
Department of Pharmacology and Therapeutics, Trinity College Dublin and Hypertension Clinic, St James's Hospital, Dublin, Ireland.
Am J Hypertens. 2008 Jun;21(6):663-7. doi: 10.1038/ajh.2008.156. Epub 2008 Apr 10.
There is conflicting information with regard to the effect of beta-blockers on arterial stiffness and wave reflection. We compared a vasodilating beta-blocker, nebivolol, with atenolol.
We randomized 40 subjects with untreated hypertension (mean +/- s.e.m. systolic/diastolic blood pressure (BP) of 160 +/- 3/98 +/- 1 mm Hg, age 49 +/- 1 years) 16 of whom were women, to atenolol 50 mg or nebivolol 5 mg daily for 4 weeks. Arterial stiffness was assessed in terms of carotid-femoral pulse wave velocity (PWV, Complior) and arterial wave reflection (augmentation index (AIx) by applanation tonometry, Sphygmocor).
Both beta-blockers produced an equal reduction in brachial BP but aortic pulse pressure (PP) was reduced to a greater extent by nebivolol (P < 0.05). PWV was decreased significantly by both therapies (nebivolol: from 11.5 +/- 0.5 to 9.9 +/- 0.5 m/s; atenolol: from 11.1 +/- 0.4 to 9.8 +/- 0.4 m/s; P < 0.01) but only nebivolol significantly reduced AIx (from 35 +/- 5 to 28 +/- 2%, P < 0.05). In addition, whereas PP amplification (PP, mm Hg) decreased with atenolol therapy (from 10 +/- 1 to 7 +/- 1, P < 0.01), it increased with nebivolol therapy (from 8 +/- 1 to 14 +/- 3, P < 0.01). Atenolol reduced heart rate to a greater extent than nebivolol did (14 +/- 3/min reduction by atenolol vs. 8 +/- 2/min reduction by nebivolol, P < 0.05). There was no difference between the two treatments in respect of the effect on transit time.
The beta-blockers, atenolol and nebivolol, have a similar effect in reducing arterial stiffness in the large elastic aorta, largely secondary to BP reduction. Nebivolol, in contrast to atenolol, has an effect on small muscular arteries, increasing PP amplification and reducing wave reflection, possibly because of increased levels of nitric oxide (NO). Such ancillary properties may impart important distinct hemodynamic effects, and therefore beta-blockers cannot be regarded as a homogeneous group.
关于β受体阻滞剂对动脉僵硬度和波反射的影响,存在相互矛盾的信息。我们比较了一种血管舒张性β受体阻滞剂奈必洛尔与阿替洛尔。
我们将40例未经治疗的高血压患者(收缩压/舒张压平均值±标准误为160±3/98±1 mmHg,年龄49±1岁)随机分组,其中16例为女性,分别给予阿替洛尔50 mg或奈必洛尔5 mg,每日一次,共4周。通过颈股脉搏波速度(PWV,Complior)和动脉波反射(应用压平式眼压计测量的增强指数(AIx),Sphygmocor)评估动脉僵硬度。
两种β受体阻滞剂均可使肱动脉血压同等程度降低,但奈必洛尔使主动脉脉压(PP)降低幅度更大(P<0.05)。两种治疗方法均使PWV显著降低(奈必洛尔:从11.5±0.5降至9.9±0.5 m/s;阿替洛尔:从11.1±0.4降至9.8±0.4 m/s;P<0.01),但只有奈必洛尔显著降低AIx(从35±5降至28±2%,P<0.05)。此外,阿替洛尔治疗使PP放大率(PP,mmHg)降低(从10±1降至7±1,P<0.01),而奈必洛尔治疗使其升高(从8±1升至14±3,P<0.01)。阿替洛尔降低心率的程度大于奈必洛尔(阿替洛尔降低14±3次/分钟,奈必洛尔降低8±2次/分钟,P<0.05)。两种治疗方法对传输时间的影响无差异。
β受体阻滞剂阿替洛尔和奈必洛尔在降低大弹性主动脉的动脉僵硬度方面具有相似的效果,这在很大程度上继发于血压降低。与阿替洛尔不同,奈必洛尔对小肌性动脉有影响,增加PP放大率并减少波反射,可能是由于一氧化氮(NO)水平升高。这些辅助特性可能产生重要的独特血流动力学效应,因此β受体阻滞剂不能被视为一个同质的类别。